1664 related articles for article (PubMed ID: 23982301)
1. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
[TBL] [Abstract][Full Text] [Related]
3. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
4. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
[TBL] [Abstract][Full Text] [Related]
6. Disentangling the association of depression on the anti-fatigue effects of ketamine.
Saligan LN; Farmer C; Ballard ED; Kadriu B; Zarate CA
J Affect Disord; 2019 Feb; 244():42-45. PubMed ID: 30312839
[TBL] [Abstract][Full Text] [Related]
7. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial.
Costi S; Soleimani L; Glasgow A; Brallier J; Spivack J; Schwartz J; Levitch CF; Richards S; Hoch M; Stade EC; Welch A; Collins KA; Feder A; Iosifescu DV; Charney DS; Murrough JW
Neuropsychopharmacology; 2019 Sep; 44(10):1812-1819. PubMed ID: 30858518
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
[TBL] [Abstract][Full Text] [Related]
9. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.
Luckenbaugh DA; Ibrahim L; Brutsche N; Franco-Chaves J; Mathews D; Marquardt CA; Cassarly C; Zarate CA
Bipolar Disord; 2012 Dec; 14(8):880-7. PubMed ID: 22978511
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
[TBL] [Abstract][Full Text] [Related]
11. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
[TBL] [Abstract][Full Text] [Related]
12. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Singh JB; Fedgchin M; Daly EJ; De Boer P; Cooper K; Lim P; Pinter C; Murrough JW; Sanacora G; Shelton RC; Kurian B; Winokur A; Fava M; Manji H; Drevets WC; Van Nueten L
Am J Psychiatry; 2016 Aug; 173(8):816-26. PubMed ID: 27056608
[TBL] [Abstract][Full Text] [Related]
13. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
[TBL] [Abstract][Full Text] [Related]
14. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF
Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029
[TBL] [Abstract][Full Text] [Related]
15. A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial.
Price RB; Spotts C; Panny B; Griffo A; Degutis M; Cruz N; Bell E; Do-Nguyen K; Wallace ML; Mathew SJ; Howland RH
Am J Psychiatry; 2022 Dec; 179(12):959-968. PubMed ID: 36128684
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression.
Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
Transl Psychiatry; 2020 Jun; 10(1):206. PubMed ID: 32591498
[TBL] [Abstract][Full Text] [Related]
17. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
DiazGranados N; Ibrahim LA; Brutsche NE; Ameli R; Henter ID; Luckenbaugh DA; Machado-Vieira R; Zarate CA
J Clin Psychiatry; 2010 Dec; 71(12):1605-11. PubMed ID: 20673547
[TBL] [Abstract][Full Text] [Related]
18. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Fava M; Freeman MP; Flynn M; Judge H; Hoeppner BB; Cusin C; Ionescu DF; Mathew SJ; Chang LC; Iosifescu DV; Murrough J; Debattista C; Schatzberg AF; Trivedi MH; Jha MK; Sanacora G; Wilkinson ST; Papakostas GI
Mol Psychiatry; 2020 Jul; 25(7):1592-1603. PubMed ID: 30283029
[TBL] [Abstract][Full Text] [Related]
19. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
[TBL] [Abstract][Full Text] [Related]
20. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans.
Zhuo C; Tian H; Li G; Chen M; Jiang D; Lin X; Xu Y; Wang W
Brain Behav; 2019 Nov; 9(11):e01423. PubMed ID: 31617335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
